Upstream Bio (UPB) vs Vanda Pharmaceuticals (VNDA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Vanda Pharmaceuticals (VNDA) has outperformed Upstream Bio (UPB) over the past year, losing 17.0% versus a loss of 76.0%. Vanda Pharmaceuticals is the larger company by market cap ($274.9 million vs $254.1 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | UPB | VNDA |
|---|---|---|
| Share price | $4.64 | $4.55 |
| Market cap | $254.14M | $274.86M |
| 1-day change | +1.98% | +0.35% |
| YTD return | -83.24% | -48.64% |
| 1-year return | -75.95% | -17.03% |
| 5-year return | — | -75.39% |
| Forward P/E | — | 22.73 |
| EPS (TTM) | $-2.88 | $-4.63 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $33.68 | $9.94 |
| 52-week low | $4.37 | $4.27 |
| Distance from 52-week high | -86.22% | -54.27% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +571.12% | +158.47% |
| Average volume | 647.42K | 974.13K |
| Shares outstanding | 54.77M | 60.46M |
| Employees | 75 | 533 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- VNDA has outperformed UPB by 58.9 percentage points over the past year.
About Upstream Bio
UPB stock →Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases focusing on severe respiratory disorders. It offers verekitug, which is in Phase 2 trials for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease and in Phase I clinical trial for treating chronic obstructive pulmonary disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 75 employees
About Vanda Pharmaceuticals
VNDA stock →Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's commercial portfolio includes Fanapt for the acute treatment of manic or mixed episodes associated with bipolar I disorder and the treatment of schizophrenia; HETLIOZ to treat non-24-hour sleep-wake disorders and nighttime sleep disturbances; PONVORY to treat relapsing forms of multiple sclerosis; and NEREUSTM for preventing vomiting induced by motion.
Health Care · Biotechnology: Pharmaceutical Preparations · 533 employees
UPB vs VNDA FAQ
Which is bigger, Upstream Bio or Vanda Pharmaceuticals?
Vanda Pharmaceuticals (VNDA) is larger, with a market capitalization of $274.86M compared with $254.14M for Upstream Bio (UPB).
Which stock has performed better over the past year, UPB or VNDA?
VNDA returned -17.03% over the past 12 months, compared with -75.95% for UPB (price return, excluding dividends). Past performance does not predict future results.
Are Upstream Bio and Vanda Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.